

**Question for written answer E-002567/2021
to the Commission**
Rule 138
Daniel Buda (PPE)

Subject: Developing countries paying more for the AstraZeneca vaccine than developed countries

Developing countries have more limited access to COVID vaccine doses and, in addition, are charged a higher price for doses compared to developed countries. An analysis by the ONE Campaign, an international organisation fighting against poverty, reports that the richest countries on the planet are set to have more than one billion excess doses, based on the current rate of COVID vaccine purchasing.

As regards the purchase price of the AstraZeneca vaccine, Bangladesh pays an average of USD 4 per dose, compared to the USD 3.5 paid by EU Member States. South Africa is also among the countries paying more for a dose of the AstraZeneca vaccine, specifically, USD 5.25 per dose. For comparison, the United States pays USD 4 per dose, but directly from the company.

Given that the EU has always been the main donor to less-developed states, how could the Commission intervene to reduce the massive discrepancy in how rich and poor countries are treated?